Advertisement
Advertisement
U.S. Markets close in 2 hrs 7 mins
Advertisement
Advertisement
Advertisement
Advertisement

ZyVersa Therapeutics, Inc. (ZVSA)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
1.9700-0.2700 (-12.05%)
As of 01:49PM EST. Market open.
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close2.2400
Open2.1800
Bid2.0100 x 800
Ask2.1000 x 1100
Day's Range1.9600 - 2.1900
52 Week Range1.3800 - 25.0000
Volume46,383
Avg. Volume353,291
Market Cap17.891M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    ZyVersa Therapeutics Reports Inducement Grant to Newly Appointed Chief Medical Officer Under Nasdaq Listing Rule 5635(c)(4)

    WESTON, Fla., Jan. 27, 2023 (GLOBE NEWSWIRE) -- ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA, or “ZyVersa”), a clinical-stage specialty biopharmaceutical company developing first-in-class drugs for treatment of renal and inflammatory diseases with high unmet medical needs, today announced the grant of an inducement equity award outside ZyVersa’s 2022 Equity Incentive Plan to its newly appointed Chief Medical Officer and Senior Vice President of Medical Affairs, Dr. Pablo Guzman. The grants were appr

  • GlobeNewswire

    ZyVersa Therapeutics to Present at BIO CEO & Investor Conference

    CEO Stephen C. Glover to provide key updates on the development status of ZyVersa’s Phase 2a-ready cholesterol efflux mediator VAR 200 for renal disease and inflammasome ASC inhibitor, IC 100 WESTON, Fla., Jan. 25, 2023 (GLOBE NEWSWIRE) -- ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA, or “ZyVersa”), a clinical stage specialty biopharmaceutical company developing first-in-class drugs for the treatment of inflammatory and renal diseases with high unmet medical needs, announced today that Stephen C. Gl

  • GlobeNewswire

    ZyVersa Therapeutics’ CEO, Stephen C. Glover, to Present at the Virtual Investor 2023 Companies to Watch Event

    Stephen C. Glover Stephen C. Glover, Co-founder, Chairman, CEO, President, ZyVersa Therapeutics Live video webcast on Wednesday, January 18th at 2:00 PM ET Mr. Glover will highlight the development status of ZyVersa’s phase 2a-ready VAR 200 for renal disease and inflammasome ASC inhibitor, IC 100 WESTON, Fla., Jan. 11, 2023 (GLOBE NEWSWIRE) -- ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA, or "ZyVersa"), a clinical-stage specialty biopharmaceutical company developing first-in-class drugs for treatmen

Advertisement
Advertisement